In the latest quarter, 7 analysts provided ratings for Bio-Techne (NASDAQ:TECH), showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ratings, ...
In the latest quarter, 7 analysts provided ratings for Bio-Techne (NASDAQ:TECH), showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the ...
The latest price target for Bio-Techne (NASDAQ:TECH) was reported by Wells Fargo on May 30, 2025. The analyst firm set a price target for $59.00 expecting TECH to rise to within 12 months (a possible ...
(RTTNews) - Gemini Bioproducts, LLC, a supplier of cell culture reagents and process liquids and healthcare private equity firm BelHealth Investment Partners, LLC announced acquisition of selected ...
Bio-Techne Corporation, a global provider of life science research tools, analytical instruments, and diagnostics, today ...
Bio-Techne Corporation (NASDAQ:TECH) is one of the most profitable biotech stocks to invest in now. On July 9, TD Cowen analyst Daniel Brennan initiated a new Buy rating on Bio-Techne Corporation ...
Bio-Techne Corporation TECH is set to release fourth-quarter fiscal 2025 results on Aug. 6, before the opening bell. The life science and diagnostic product maker posted adjusted earnings per share ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results